Company intelligence / Profile preview

Novelrad

Ownership: Private
Development stage: Preclinical

Overview

Novelrad is developing a proprietary, minimally invasive micro-suturing technology designed for vascular and heart defect closure. The platform aims to improve clinical outcomes, reduce procedure time, and shorten hospital stays. The company has received significant non-dilutive funding from the European Innovation Council Accelerator program (€2.5 million grant) and is positioning its technology as a disruptive solution for unmet needs in large bore vascular closure procedures. No published clinical trial results are available as of January 2025.

Therapeutic areas: Cardiovascular
Modalities: Device (specifically, minimally invasive suturing device)
Industry: Surgical Medical Devices

Partnerships

European Innovation Council Accelerator program / EISMEA grant recipient

Beyond the preview

Go deeper on Novelrad.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novelrad.

Explore the full profile